Marshall Wace, LLP Eiger Bio Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $25,487 - $186,910	24,988 New	24,988 $29,000
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $171,221 - $307,444	-34,313 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.84 - $9.74 $131,761 - $334,208	34,313 New	34,313 $285,000
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $683,814 - $1.05 Million	-85,691 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $257,712 - $402,109	32,376 Added 60.73%	85,691 $698,000
Q2 2020 Aug 13, 2020	SELL	$5.4 - $13.37 $168,604 - $417,451	-31,223 Reduced 36.93%	53,315 $512,000
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $415,081 - $1.24 Million	84,538 New	84,538 $575,000
Q4 2019 Feb 14, 2020	SELL	$9.77 - $15.66 $51,927 - $83,232	-5,315 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$9.59 - $12.0 $50,970 - $63,780	5,315 New	5,315 $55,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.